In fact, a high mutational burden seems to behave as a predictive marker of response to ICK-based therapies only when the CD8+ infiltration level correlates with the neoantigen load (such as melanoma, lung, bladder cancers, and colon cancer). Here, CD8A is linked to melanoma.